MedTrace Logo

Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia

NCT00607256 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2019-12-13

No results posted yet for this study

Summary

To evaluate the lon-term safety and tolerability of \[S,S\]-reboxetine in patients with fibromyalgia

Conditions

  • Fibromyalgia

Interventions

DRUG

[S,S]-reboxetine

S\_S reboxetine dosed daily.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-20
Primary Completion
2009-05-18
Completion
2009-05-18

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Netherlands
  • South Africa
  • South Korea
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607256 on ClinicalTrials.gov